Keyword

disability progression

Description: The worsening or accumulation over time of functional limitations associated with a disease or other health condition.

Primary topic: Multiple Sclerosis Research Studies (87%)

OpenAlex ID: keywords/disability-progression

Multiple sclerosis

2008 · Alastair Compston, Alasdair Coles · The Lancet · 4,442

New Multiple Sclerosis Phenotypic Classification

2014 · Fred D. Lublin · European Neurology · 4,260

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 · Chris H. Polman, Paul W. O'Connor, et al. · New England Journal of Medicine · 3,392

PDF

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function

1999 · Jesse M. Cedarbaum, Nancy Stambler, et al. · Journal of the Neurological Sciences · 3,302

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

2010 · Ludwig Kappos, Ernst-Wilhelm Radue, et al. · New England Journal of Medicine · 2,646

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 · Lawrence D. Jacobs, Diane L. Cookfair, et al. · Annals of Neurology · 2,450

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 · Jeffrey A. Cohen, Frederik Barkhof, et al. · New England Journal of Medicine · 2,204

PDF

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 · The IFNB Multiple Sclerosis Study Group · Neurology · 2,085

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 · George C Ebers · The Lancet · 2,074

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

2016 · Stephen L. Hauser, Amit Bar-Or, et al. · New England Journal of Medicine · 2,020

PDF

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

2016 · Xavier Montalban, Stephen L. Hauser, et al. · New England Journal of Medicine · 1,906

PDF

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 · K. P. Johnson, B. R. Brooks, et al. · Neurology · 1,898

The clinical course of neuromyelitis optica (Devic’s syndrome)

1999 · Dean M. Wingerchuk, William F. Hogancamp, et al. · Neurology · 1,822

Multiple sclerosis

2002 · Alastair Compston, Alasdair Coles · The Lancet · 1,745

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

2012 · Ralf Gold, Ludwig Kappos, et al. · New England Journal of Medicine · 1,735

Rate of Pregnancy-Related Relapse in Multiple Sclerosis

1998 · Christian Confavreux, Michael Hutchinson, et al. · New England Journal of Medicine · 1,561

PDF

The Natural History of Multiple Sclerosis: a Geographically Based Study

1989 · B. G. WEINSHENKER, B. BASS, et al. · Brain · 1,453

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology

2006 · R. Magliozzi, O. Howell, et al. · Brain · 1,448

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

2012 · Robert J. Fox, David H. Miller, et al. · New England Journal of Medicine · 1,355

PDF

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

2006 · Richard A. Rudick, William H. Stuart, et al. · New England Journal of Medicine · 1,345

PDF

Relapses and Progression of Disability in Multiple Sclerosis

2000 · Christian Confavreux, Sandra Vukusic, et al. · New England Journal of Medicine · 1,309

PDF

Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease

1993 · The Parkinson Study Group · New England Journal of Medicine · 1,223

PDF

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 · Jeffrey A Cohen, Alasdair J Coles, et al. · The Lancet · 1,209

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 · Alasdair J Coles, Cary L Twyman, et al. · The Lancet · 1,203

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1999 · G. R. Cutter · Brain · 1,191

Works count: 11,710

Citation count: 347,800